US7056916B2
(en)
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
ES2380370T3
(es)
*
|
2004-04-22 |
2012-05-11 |
Boehringer Ingelheim International Gmbh |
Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
|
DE102004019539A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
|
JP2007537187A
(ja)
*
|
2004-05-13 |
2007-12-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
|
DE102004024453A1
(de)
*
|
2004-05-14 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
|
DE102004024452A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Aerosolformulierung für die Inhalation von Betaagonisten
|
US20050256115A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Boehringer Ingelheim International Gmbh |
Aerosol formulation for the inhalation of beta-agonists
|
DE102004024454A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004024451A1
(de)
*
|
2004-05-14 |
2005-12-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
|
US7745621B2
(en)
|
2004-05-14 |
2010-06-29 |
Boehringer Ingelheim International Gmbh |
Long acting bronchodilators for the treatment of respiratory diseases
|
US7220742B2
(en)
|
2004-05-14 |
2007-05-22 |
Boehringer Ingelheim International Gmbh |
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
DE102004045648A1
(de)
*
|
2004-09-21 |
2006-03-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Betamimetika zur Behandlung von Atemwegserkrankungen
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
DE102005007654A1
(de)
|
2005-02-19 |
2006-08-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
DE102005030733A1
(de)
*
|
2005-07-01 |
2007-01-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
KR20080036632A
(ko)
|
2005-08-08 |
2008-04-28 |
아젠터 디스커버리 리미티드 |
바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
|
CA2619402C
(en)
|
2005-08-15 |
2015-02-03 |
Boehringer Ingelheim International Gmbh |
Method for producing betamimetics
|
US20070086957A1
(en)
*
|
2005-10-10 |
2007-04-19 |
Thierry Bouyssou |
Combination of medicaments for the treatment of respiratory diseases
|
US20070088030A1
(en)
*
|
2005-10-10 |
2007-04-19 |
Barbara Niklaus-Humke |
Aerosol formulations for the inhalation of beta-agonists
|
CA2625664C
(en)
|
2005-10-21 |
2016-01-05 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
AU2006311060A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Boehringer Ingelheim International Gmbh |
Aerosolformulation for inhalation
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
JP2009526817A
(ja)
*
|
2006-02-16 |
2009-07-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
呼吸器疾患の治療用医薬組成物
|
PE20080142A1
(es)
|
2006-03-15 |
2008-04-14 |
Boehringer Ingelheim Int |
Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
|
PT2322525E
(pt)
|
2006-04-21 |
2013-12-26 |
Novartis Ag |
Derivados de purina para utilização como agonistas do recetor de adenosina a2a
|
EP2057152A1
(de)
*
|
2006-08-07 |
2009-05-13 |
Boehringer Ingelheim International GmbH |
Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
|
UY30542A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de agonistas beta
|
UY30543A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de beta- agonistas
|
CA2664378A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
CA2667962A1
(en)
|
2006-10-30 |
2008-05-08 |
Novartis Ag |
Heterocyclic compounds as antiinflammatory agents
|
AU2007342223B2
(en)
|
2007-01-10 |
2011-02-24 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
ES2370952T3
(es)
*
|
2007-01-25 |
2011-12-26 |
Boehringer Ingelheim International Gmbh |
Procedimiento para la preparación de betamiméticos.
|
ES2361595T3
(es)
|
2007-05-07 |
2011-06-20 |
Novartis Ag |
Compuestos orgánicos.
|
MX2010006421A
(es)
|
2007-12-10 |
2010-06-25 |
Novartis Ag |
Compuestos organicos.
|
AU2009203693B2
(en)
|
2008-01-11 |
2012-06-07 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
EP2300010B1
(en)
|
2008-06-10 |
2015-03-04 |
Novartis AG |
Pyrazine derivatives as epithelial sodium channel blockers
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
EA019441B1
(ru)
|
2008-12-30 |
2014-03-31 |
Палмаджен Терепьютикс (Инфлеммейшн) Лимитед |
Сульфонамиды, предназначенные для лечения респираторных нарушений
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
CA2770873A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
IN2012DN01961A
(hu)
|
2009-08-17 |
2015-08-21 |
Intellikine Llc |
|
WO2011050325A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
ES2886022T3
(es)
*
|
2010-09-21 |
2021-12-16 |
Intekrin Therapeutics Inc |
Composiciones farmacéuticas sólidas antidiabéticas
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
SG192795A1
(en)
|
2011-02-25 |
2013-09-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
US9174994B2
(en)
|
2011-11-23 |
2015-11-03 |
Intellikine, Llc |
Enhanced treatment regimens using mTor inhibitors
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
RU2660354C2
(ru)
|
2012-04-03 |
2018-07-05 |
Новартис Аг |
Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
|
EP2906218B1
(en)
|
2012-10-09 |
2016-12-14 |
Boehringer Ingelheim International GmbH |
Beta-2-adrenoceptor agonist for the treatment of cough
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
KR20160141855A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
|
PL3134395T3
(pl)
|
2014-04-24 |
2018-07-31 |
Novartis Ag |
Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
|
PT3134396T
(pt)
|
2014-04-24 |
2019-12-16 |
Novartis Ag |
Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CN107207510B
(zh)
|
2014-07-31 |
2019-11-29 |
诺华股份有限公司 |
联合疗法
|
JP2019536812A
(ja)
|
2016-12-12 |
2019-12-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
|
WO2018114887A1
(en)
|
2016-12-20 |
2018-06-28 |
Laboratorios Lesvi, S.L. |
Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
|
CN108997248B
(zh)
*
|
2018-08-06 |
2023-08-01 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型b及其制备方法
|
CN109096218B
(zh)
*
|
2018-08-06 |
2020-10-27 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型a及其制备方法
|
CN113891744A
(zh)
|
2019-06-10 |
2022-01-04 |
诺华股份有限公司 |
用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
|
KR20220052934A
(ko)
|
2019-08-28 |
2022-04-28 |
노파르티스 아게 |
치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
|
WO2021252577A1
(en)
*
|
2020-06-09 |
2021-12-16 |
Anovent Pharmaceutical (U.S.), Llc |
Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
|
US11331322B1
(en)
|
2021-09-15 |
2022-05-17 |
Santen Pharmaceutical Co., Ltd. |
Medicament for preventing and/or treating dry eye
|